Figure S8 from A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma

Key Points

• Main finding reveals that multi-selective inhibitor combination therapy can control tumors long-term.
• Data suggest this approach fosters senescence-associated tumor-immune equilibrium in pancreatic ductal adenocarcinoma.
• Flow cytometry was used to analyze immune cell responses in the tumor environment.
• This work provides insights into potential new treatments for pancreatic cancer, aiming for improved patient outcomes.